SCHEMBL7587888

SCHEMBL7587888

Cc1ccc(S(=O)(=O)Nc2ccc(C#N)cc2NS(=O)(=O)c2ccc(C)cc2)cc1

nearest known ligand 0.69

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KEAP1 Q14145 1/20 0.54
NFE2L2 Q16236 1/20 0.54
ALDH1A1 P00352 2/20 0.50
HSD11B1 P28845 2/20 0.50
LMNA P02545 2/20 0.50
KMT2A Q03164 1/20 0.50
USP2 O75604 1/20 0.50
POLB P06746 1/20 0.50
MAPT P10636 1/20 0.50
CYP2C9 P11712 1/20 0.50
CYP2C19 P33261 1/20 0.50
NOD2 Q9HC29 1/20 0.50
L3MBTL1 Q9Y468 1/20 0.50
CA1 P00915 1/20 0.50
CA2 P00918 1/20 0.50
CA4 P22748 1/20 0.50
CA7 P43166 1/20 0.50
CA9 Q16790 1/20 0.50
GAA P10253 1/20 0.49
GFER P55789 1/20 0.49

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6554639 0.88 KEAP1 (0.51) KEAP1NFE2L2ALDH1A1HSD11B1LMNA
SCHEMBL6831807 0.87 MAPT (0.54) KEAP1NFE2L2ALDH1A1HSD11B1LMNA
SCHEMBL10238213 0.86 KEAP1 (0.49) KEAP1NFE2L2ALDH1A1HSD11B1LMNA
SCHEMBL7589336 0.84 SLC22A12 (0.54) ACLY
SCHEMBL7590378 0.84 CCR2 (0.48) HSD11B1MAPTGAAACLYSMN1; SMN2
SCHEMBL23200283 0.84 METAP2 (0.67) LMNAPOLBCYP2C9CYP2C19L3MBTL1
SCHEMBL6553589 0.84 MAPT (0.60) KEAP1NFE2L2ALDH1A1HSD11B1LMNA
SCHEMBL617823 0.84 SLC22A12 (0.51) KEAP1NFE2L2ALDH1A1HSD11B1KMT2A
SCHEMBL6554533 0.84 MAPT (0.60) KEAP1NFE2L2ALDH1A1HSD11B1LMNA
SCHEMBL22654320 0.83 ALDH1A1 (0.54) KEAP1NFE2L2ALDH1A1LMNAUSP2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9856230-B2 Enzyme inhibitors UNIVERSITY OF SUNDERLAND (GB) 2018-01-02 US disclosed
US-20150322035-A1 Enzyme Inhibitors UNIVERSITY OF SUNDERLAND (GB) 2015-11-12 US disclosed
WO-2014096864-A9 ENZYME INHIBITORS UNIVERSITY OF SUNDERLAND (GB) 2015-03-05 WO disclosed
WO-2014096864-A1 ENZYME INHIBITORS UNIVERSITY OF SUNDERLAND (GB) 2014-06-26 WO disclosed
EP-1239852-A2 BISSULFONAMIDE DERIVATIVES AS ENZYME INHIBITORS Arrow Therapeutics Limited (GB) 2002-09-18 EP disclosed
WO-2001028537-A2 BISSULFONAMIDE DERIVATIVES AS ENZYME INHIBITORS ARROW THERAPEUTICS LIMITED (GB) 2001-04-26 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20150322035-A1 Enzyme Inhibitors TXNRD3, TXNRD2, TXNRD1 KEAP1 142/4885NFE2L2 108/4885ALDH1A1 687/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.